Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Employees - 1543, CEO - Mr. John Charles Jacobs M.B.A., Sector - Healthcare, Country - US, Market Cap - 1.40B

Altman ZScore(max is 10): -3.7, Piotroski Score(max is 10): 4, Working Capital: $-77319000, Total Assets: $1712483000, Retained Earnings: $-4927420000, EBIT: -263128000, Total Liabilities: $2238919000, Revenue: $885193000

- Current Price $8.70 - Analyst Target Price $16.00